Loss of PRDM11 promotes MYC-driven lymphomagenesis

Blood

Volumn 125, Issue 8, 2015, Pages 1272-1281

  Fog, Cathrine Kolster ^a   Asmar, Fazila ^b   Côme, Christophe ^a   Jensen, Klaus Thorleif ^a   Johansen, Jens Vilstrup ^a   Kheir, Tony Bou ^a   Jacobsen, Linda ^a   Friis, Carsten ^a   Louw, Alison ^a   Rosgaard, Louise ^a   Øbro, Nina Friesgaard ^b   Marquart, Hanne Vibeke ^b   Anthonsen, Kristian ^b   Braat, Arie Koen ^c   Van Lohuizen, Maarten ^c   Ralfkiaer, Elisabeth ^b   Grønbæk, Kirsten ^a,b   Lund, Anders Henrik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; RITUXIMAB; TRANSCRIPTOME; VINCRISTINE; CARRIER PROTEIN; MYC PROTEIN, MOUSE; PRDM11 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; FEMALE; GENE MAPPING; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMAGENESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; ONCOGENE C JUN; OVERALL SURVIVAL; PRDM11 GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; ANIMAL EMBRYO; CELL CULTURE; CELL TRANSFORMATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EMBRYO, MAMMALIAN; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HELA CELLS; HUMANS; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEINS;

EID: 84923365961     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-560805     Document Type: Article

References (51)

1. Fog CK, Galli GG, Lund AH. PRDM proteins: important players in differentiation and disease. BioEssays. 2012;34(1):50-60.
2. Hohenauer T, Moore AW. The Prdm family: expanding roles in stem cells and development. Development. 2012;139(13):2267-2282.
3. Fumasoni I, Meani N, Rambaldi D, Scafetta G, Alcalay M, Ciccarelli FD. Family expansion and gene rearrangements contributed to the functional specialization of PRDM genes in vertebrates. BMC Evol Biol. 2007;7:187.
4. Sun X-J, Xu P-F, Zhou T, et al. Genome-wide survey and developmental expression mapping of zebrafish SET domain-containing genes. PLoS ONE. 2008;3(1):e1499.
5. Huang S, Shao G, Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem. 1998;273(26): 15933-15939.
6. Kim K-C, Geng L, Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 2003;63(22): 7619-7623.
7. Pinheiro I, Margueron R, Shukeir N, et al. Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell. 2012;150(5):948-960.
8. Eom G-H, Kim K, Kim S-M, et al. Histone methyltransferase PRDM8 regulates mouse testis steroidogenesis. Biochem Biophys Res Commun. 2009;388(1):131-136.
9. Hayashi K, Yoshida K, Matsui Y. A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. Nature. 2005; 438(7066):374-378.
10. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107(10):4090-4100.
11. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203(2):311-317.
12. Galli GG, Multhaupt HA, Carrara M, et al. Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression. Oncogene. 2014;33(25):3342-3350.
13. Watanabe Y, Toyota M, Kondo Y, et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res. 2007;13(16):4786-4794.
14. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976-990.
15. Hummel M, Bentink S, Berger H, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430.
16. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
17. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046): 533-538.
18. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371.
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1): 11-30.
20. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
21. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
22. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era.; Nat Rev Clin Oncol. 2014;11 (1):12-23.
23. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Mycinduced apoptosis via INK4a/ARF. Genes Dev. 1999;13(20):2678-2690.
24. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
25. Sjö LD, Poulsen CB, Hansen M, Møller MB, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol. 2007;79(6):501-507.
26. Caron G, Le Gallou S, Lamy T, Tarte K, Fest T. CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol. 2009;182(12): 7595-7602.
27. Galli GG, Honnens de Lichtenberg K, Carrara M, et al. Prdm5 regulates collagen gene transcription by association with RNA polymerase II in developing bone. PLoS Genet. 2012;8(5): e1002711.
28. Briknarová K, Atwater DZ, Glicken JM, Maynard SJ, Ness TE. The PR/SET domain in PRDM4 is preceded by a zinc knuckle. Proteins. 2011;79(7): 2341-2345.
29. Loth DW, Artigas MS, Gharib SA, et al. Genomewide association analysis identifies six new loci associated with forced vital capacity. Nat Genet. 2014;46(7):669-677.
30. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009;137(3): 413-431.
31. Mazur PK, Reynoird N, Khatri P, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510(7504):283-287.
32. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20): 2658-2669.
33. Mori S, Rempel RE, Chang JT, et al. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res. 2008; 68(20):8525-8534.
34. Martins CP, Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 2002;21(14):3739-3748.
35. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA. 2004;101(16): 6164-6169.
36. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol. 2001;21(22): 7653-7662.
37. Price DH. Poised polymerases: on your mark.get set.go! Mol Cell. 2008;30(1):7-10.
38. Ricketts SL, Carter JC, Coleman WB. Identification of three 11p11.2 candidate liver tumor suppressors through analysis of known human genes. Mol Carcinog. 2003;36(2):90-99.
39. Ruivenkamp CAL, van Wezel T, Zanon C, et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet. 2002;31(3): 295-300.
40. Calado DP, Zhang B, Srinivasan L, et al. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18(6):580-589.
41. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18(6):568-579.
42. Thoren LA, Fog CK, Jensen KT, et al. PRDM11 is dispensable for the maintenance and function of hematopoietic stem and progenitor cells. Stem Cell Res (Amst). 2013;11(3):1129-1136.
43. Gyory I, Wu J, Fejér G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol. 2004;5(3):299-308.
44. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol. 2000;20(7): 2592-2603.
45. Duan Z, Person RE, Lee H-H, et al. Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol. 2007;27(19):6889-6902.
46. Baudat F, Buard J, Grey C, et al. PRDM9 is a major determinant of meiotic recombination hotspots in humans and mice. Science. 2010; 327(5967):836-840.
47. Myers S, Bowden R, Tumian A, et al. Drive against hotspot motifs in primates implicates the PRDM9 gene in meiotic recombination. Science. 2010;327(5967):876-879.
48. Ma Z, Swigut T, Valouev A, Rada-Iglesias A, Wysocka J. Sequence-specific regulator Prdm14 safeguards mouse ESCs from entering extraembryonic endoderm fates. Nat Struct Mol Biol. 2011;18(2):120-127.
49. Chia N-Y, Chan Y-S, Feng B, et al. A genomewide RNAi screen reveals determinants of human embryonic stem cell identity. Nature. 2010; 468(7321):316-320.
50. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761-774.
51. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994;77(2): 297-306.